Annual Cash & Cash Equivalents
$37.23 M
-$48.16 M-56.40%
September 30, 2024
Summary
- As of February 8, 2025, ENTA annual cash & cash equivalents is $37.23 million, with the most recent change of -$48.16 million (-56.40%) on September 30, 2024.
- During the last 3 years, ENTA annual cash & cash equivalents has fallen by -$19.97 million (-34.91%).
- ENTA annual cash & cash equivalents is now -57.27% below its all-time high of $87.13 million, reached on September 30, 2020.
Performance
ENTA Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Cash And Cash Equivalents
$37.23 M
+$1.46 M+4.08%
September 30, 2024
Summary
- As of February 8, 2025, ENTA quarterly cash and cash equivalents is $37.23 million, with the most recent change of +$1.46 million (+4.08%) on September 30, 2024.
- Over the past year, ENTA quarterly cash and cash equivalents has dropped by -$48.16 million (-56.40%).
- ENTA quarterly cash and cash equivalents is now -64.88% below its all-time high of $106.03 million, reached on March 31, 2019.
Performance
ENTA Quarterly Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash And Cash Equivalents Formula
Cash & Cash Equivalents = Cash + Short-Term Investments
ENTA Cash And Cash Equivalents Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -56.4% | -56.4% |
| 3 y3 years | -34.9% | -34.9% |
| 5 y5 years | -27.3% | -34.9% |
ENTA Cash And Cash Equivalents Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -56.4% | at low | -62.4% | +31.3% |
| 5 y | 5-year | -57.3% | at low | -62.7% | +709.2% |
| alltime | all time | -57.3% | +444.6% | -64.9% | +840.0% |
Enanta Pharmaceuticals Cash And Cash Equivalents History
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2024 | $37.23 M(-56.4%) | $37.23 M(+4.1%) |
| Jun 2024 | - | $35.77 M(-43.7%) |
| Mar 2024 | - | $63.54 M(+59.1%) |
| Dec 2023 | - | $39.93 M(-53.2%) |
| Sep 2023 | $85.39 M(+94.1%) | $85.39 M(-10.3%) |
| Jun 2023 | - | $95.18 M(+30.1%) |
| Mar 2023 | - | $73.18 M(+73.3%) |
| Dec 2022 | - | $42.22 M(-4.0%) |
| Sep 2022 | $43.99 M(-23.1%) | $43.99 M(+55.1%) |
| Jun 2022 | - | $28.37 M(-30.8%) |
| Mar 2022 | - | $40.99 M(-58.6%) |
| Dec 2021 | - | $99.07 M(+73.2%) |
| Sep 2021 | $57.21 M(-34.3%) | $57.21 M(+1143.3%) |
| Jun 2021 | - | $4.60 M(-94.0%) |
| Mar 2021 | - | $77.13 M(+40.0%) |
| Dec 2020 | - | $55.09 M(-36.8%) |
| Sep 2020 | $87.13 M(+70.1%) | $87.13 M(-12.7%) |
| Jun 2020 | - | $99.86 M(+34.3%) |
| Mar 2020 | - | $74.34 M(+169.8%) |
| Dec 2019 | - | $27.56 M(-46.2%) |
| Sep 2019 | $51.23 M(-19.8%) | $51.23 M(-45.6%) |
| Jun 2019 | - | $94.21 M(-11.2%) |
| Mar 2019 | - | $106.03 M(+42.6%) |
| Dec 2018 | - | $74.36 M(+16.4%) |
| Sep 2018 | $63.90 M | $63.90 M(+50.4%) |
| Date | Annual | Quarterly |
|---|---|---|
| Jun 2018 | - | $42.48 M(-36.5%) |
| Mar 2018 | - | $66.93 M(-1.7%) |
| Dec 2017 | - | $68.05 M(+3.6%) |
| Sep 2017 | $65.67 M(+296.2%) | $65.67 M(+195.0%) |
| Jun 2017 | - | $22.26 M(+15.9%) |
| Mar 2017 | - | $19.21 M(-6.8%) |
| Dec 2016 | - | $20.62 M(+24.4%) |
| Sep 2016 | $16.58 M(-23.7%) | $16.58 M(-33.1%) |
| Jun 2016 | - | $24.79 M(-56.0%) |
| Mar 2016 | - | $56.36 M(+21.9%) |
| Dec 2015 | - | $46.23 M(+112.8%) |
| Sep 2015 | $21.73 M(-29.2%) | $21.73 M(+9.5%) |
| Jun 2015 | - | $19.84 M(-22.9%) |
| Mar 2015 | - | $25.75 M(-24.6%) |
| Dec 2014 | - | $34.13 M(+11.2%) |
| Sep 2014 | $30.70 M(+246.5%) | $30.70 M(+16.4%) |
| Jun 2014 | - | $26.37 M(+45.7%) |
| Mar 2014 | - | $18.10 M(+309.0%) |
| Dec 2013 | - | $4.43 M(-50.0%) |
| Sep 2013 | $8.86 M(-15.7%) | $8.86 M(-53.1%) |
| Jun 2013 | - | $18.88 M(-74.6%) |
| Mar 2013 | - | $74.46 M(+259.1%) |
| Dec 2012 | - | $20.73 M(+97.3%) |
| Sep 2012 | $10.51 M(+53.7%) | $10.51 M(+165.4%) |
| Jun 2012 | - | $3.96 M(-42.1%) |
| Sep 2011 | $6.84 M | $6.84 M |
FAQ
- What is Enanta Pharmaceuticals annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for Enanta Pharmaceuticals?
- What is Enanta Pharmaceuticals annual cash & cash equivalents year-on-year change?
- What is Enanta Pharmaceuticals quarterly cash and cash equivalents?
- What is the all time high quarterly cash and cash equivalents for Enanta Pharmaceuticals?
- What is Enanta Pharmaceuticals quarterly cash and cash equivalents year-on-year change?
What is Enanta Pharmaceuticals annual cash & cash equivalents?
The current annual cash & cash equivalents of ENTA is $37.23 M
What is the all time high annual cash & cash equivalents for Enanta Pharmaceuticals?
Enanta Pharmaceuticals all-time high annual cash & cash equivalents is $87.13 M
What is Enanta Pharmaceuticals annual cash & cash equivalents year-on-year change?
Over the past year, ENTA annual cash & cash equivalents has changed by -$48.16 M (-56.40%)
What is Enanta Pharmaceuticals quarterly cash and cash equivalents?
The current quarterly cash and cash equivalents of ENTA is $37.23 M
What is the all time high quarterly cash and cash equivalents for Enanta Pharmaceuticals?
Enanta Pharmaceuticals all-time high quarterly cash and cash equivalents is $106.03 M
What is Enanta Pharmaceuticals quarterly cash and cash equivalents year-on-year change?
Over the past year, ENTA quarterly cash and cash equivalents has changed by -$48.16 M (-56.40%)